ReviewNigerian medical journal : journal of the Nigeria Medical Association
Neoadjuvant Chemotherapy Response in Breast Cancer among Nigerian Women: A Systematic Review and Meta-Analysis (2000-2025).
Review in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemotherapy (NACT) is increasingly employed for locally advanced breast cancer in Nigeria, but treatment outcomes remain heterogeneous and often uncertain relative to global standards. Methodology: We systematically reviewed Nigerian studies on NACT outcomes using PubMed, Embase, Scopus, Web of Science, AJOL, and grey literature through September 2025. Eligible studies included women receiving NACT who reported an objective response rate (ORR) or a pathologic complete response (pCR). Quality was assessed using ROBINS-I or RoB-2, and certainty was rated using GRADE. Pooled estimates were generated with random-effects (DerSimonian-Laird) models. Results: Eleven studies (n = 629 women) met the inclusion criteria. Early anthracycline-based cohorts showed ORR = 51-93% with rare pCR. Contemporary anthracycline-taxane regimens achieved pCR ≈ 20%, the highest in HER2-positive and triple-negative disease. Pooled ORR = 66% (95% CI: 55-76%; I Conclusions: NACT in Nigeria achieves consistent clinical downstaging but modest pCR outside HER2-targeted settings. Expanding access to biomarker testing, taxanes, trastuzumab (including biosimilars), and ensuring therapy completion are essential to close the global outcome gap.
Indexed as
Identifiers
42544249PMC13429092What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.